Metabolic Research
Retatrutide
Retatrutide is a synthetic peptide studied for coordinated activation of three metabolic hormone receptors, with human research examining glucose regulation, appetite, body weight and liver fat.
KPV is a three-residue fragment of alpha-MSH studied for cellular inflammatory signaling and intestinal inflammation in preclinical models.
Explore the research profileSubmit an unpaid laboratory order request for manual review. Availability and any pending amounts require confirmation.
Catalog quantities are not assay results.
Alpha-MSH-derived tripeptide
KPV denotes the amino acids lysine, proline, and valine, corresponding to the final three residues of alpha-melanocyte-stimulating hormone. Studying this short fragment does not make it interchangeable with the complete hormone. Most relevant evidence concerns cultured cells and experimental intestinal inflammation in mice.
This reference describes the published literature. Exact supplied form and chemical specifications require product-specific documentation. The studies are linked in Selected literature.
A mechanistic study identified uptake through the peptide transporter PepT1 in intestinal epithelial and immune-cell models, followed by reduced activation of inflammatory signaling pathways including NF-kappaB and MAP kinases. Separate mouse experiments suggest that some effects can occur without a functional melanocortin-1 receptor.
Experiments using epithelial cell lines and a T-cell line linked KPV transport to reduced inflammatory responses. These systems help examine how access to intracellular compartments affects activity; human-derived cells are not evidence from treated human participants. [1]
A study using chemically induced and immune-cell-transfer colitis reported changes in weight recovery, inflammatory infiltrates, and tissue injury. Findings in mice lacking functional melanocortin-1 receptors supported investigation of mechanisms beyond that receptor alone. [2]
Researchers incorporated KPV into hyaluronic-acid-functionalized nanoparticles to investigate delivery to inflamed intestinal tissue. The resulting mouse findings concern an engineered formulation, so they cannot be assigned automatically to free KPV or a different preparation. [3]
Study topics describe the cited models, not established benefits of this catalog material.
The cited work supports preclinical investigation of transport, local inflammatory signaling, and formulation design. It does not demonstrate treatment of human inflammatory bowel disease. Reduced inflammatory markers and improved mouse disease scores remain intermediate evidence rather than established clinical outcomes.
Transporter expression, disease model, tissue exposure, and delivery system can substantially change experimental results. The presence of a fragment within a natural hormone does not establish the safety or effectiveness of supplying that fragment separately. No cited study validates a WYZ Labs formulation or proves benefit in people.
Primary studies and clearly identified supporting sources. Each link opens the original record.
PepT1 uptake and inflammatory signaling in cell systems, with mouse colitis experiments.
Two mouse colitis models and melanocortin-1 receptor experiments.
Engineered nanoparticle delivery in preclinical systems; not a human ulcerative-colitis trial.
Literature reviewed October 2026. This is a selected research overview, not an exhaustive systematic review. Published findings do not establish the identity, purity, sterility or suitability of any WYZ batch. For laboratory research only; not for human or veterinary use.
Final product specifications and product-specific storage instructions have not been supplied. Review the original documentation and your laboratory’s procedures before obtaining or using the material.
For qualified laboratory researchers. Not for human or veterinary use. Product information is not medical advice or a recommendation for personal use.
What to look for in a COA